In the ESCC PD-L1 CPS ≥ 10 subgroup, 26 of 44 patients (59.1%) receiving pembrolizumab–chemotherapy and 10 of 32 (31.3%) receiving placebo–chemotherapy achieved objective response; median DOR (range) was 10.5 (2.3 + 28.9 +) and 4.4 months (3.5–17.0), respectively. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.